Xiang Lei ointment for healing diabetic-related ulcers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, controlled study at Peking University Third Hospital comparing Xiang Lei ointment plus clinical standard treatment versus clinical standard treatment alone for diabetic-related ulcers. Eligible adults with type 1 or type 2 diabetes and a diabetic ulcer in the granulation phase (with HbA1c <10% at enrollment) are randomized to topical Xiang Lei application plus usual wound care or to usual wound care alone. Participants receive regular wound assessments, infection monitoring, and safety labs, with outcomes focused on wound healing, infection control, and adverse events. The trial is motivated by preclinical rationale that modulating macrophage polarization may help transition chronic wounds from a pro-inflammatory to a proliferative phase to promote repair.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* a confirmed diagnosis of type 1 or type 2 diabetes mellitus that meets the standard World Health Organization definition, with blood glucose controlled prior to enrolment and a glycated haemoglobin HbA1c level of less than 10%;
* the type of wound is an ulcer;
* the wound etiology is diabetic, mainly abnormalities in blood glucose, resulting in poor or prolonged healing and requiring standard wound therapy;
* the staging of the wound is in the granulation phase;
* voluntary participation in the study and signing of an informed consent form.

Exclusion Criteria:

* acute heart attack, heart failure, hepatitis, shock, expiratory failure and other serious diseases that have not been corrected;
* uncontrolled blood glucose, fasting blood glucose \> 15 mmol/L and glycated haemoglobin \> 12%;
* active bleeding in the wound, which does not allow the implementation of the conventional basic treatment plan;
* serum albumin \< 20 g/L; haemoglobin \< 60 g/L; platelets \< 50 x 109/L;
* a state of disseminated infection that is being or will be treated with antibiotics
* patients with advanced malignant tumours;
* active autoimmune disease;
* previous allergy to topical human granulocyte macrophage stimulating factor gel (Jinfuning);
* inability of the patient to co-operate or mental disorder;
* in the judgement of the investigator, the subject has a clearly irremovable cause of wound healing, is unsuitable for the study or is unable to comply with the requirements of the study.

Where it's running

• Peking University 3rd Hospital
  Beijing, Beijing Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PowerHeal Bioelectric Bandage for infected open wound recovery

  This tests whether the PowerHeal™ Bioelectric Bandage helps adults with infected traumatic wounds heal faster and clear infection better than standard dressings.

  Recruiting University of Pittsburgh · Ivano-Frankivsk · NCT07329114

• Vacuum Sealing Drainage to Help Wound Healing After Ob/Gyn Surgical Site Infections

  This study tests whether Vacuum Sealing Drainage (VSD) helps wounds heal faster and reduces complications after obstetric or gynecologic surgeries when infections occur.

  Recruiting Minia University · Minya · NCT07525674

• Cold atmospheric plasma to improve cannulation-site wound healing after extracorporeal life support

  This trial will test whether adding cold atmospheric plasma (CAP) to standard wound care helps adults on extracorporeal life support heal cannulation-site wounds faster and with fewer infections.

  Recruiting National Taiwan University Hospital · Taipei · NCT07501897

• Antibacterial absorbable polyester dressing for chronic non-healing wounds

  This trial will test an antimicrobial absorbable polyester dressing to see if it helps adults with chronic non-healing ulcers heal faster and safely.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07261501

• Ev.FV to heal wounds in dystrophic epidermolysis bullosa

  This trial will test whether Ev.FV, a mesenchymal stem cell-derived extracellular vesicle therapy, helps heal wounds in people with dystrophic epidermolysis bullosa.

  Recruiting Phase 1/2 Isfahan University of Medical Sciences · Isfahan · NCT07230223

• New gel treatment for venous leg ulcers

  This study is testing a new gel treatment for people with stubborn venous leg ulcers to see if it helps them heal better than just the usual care.

  Recruiting at 5 sites Phase 3 TR Therapeutics · Jacksonville, Florida and 11 other locations · NCT06707103

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.